Navigation Links
Singapore research organisations team up to advance drug discovery using brain tumor stem cells
Date:2/17/2009

Lilly Singapore Centre for Drug Discovery (LSCDD), Singapore's National Neuroscience Institute (NNI), and the Singapore Institute for Clinical Sciences (SICS), have teamed up to advance drug discovery using adult brain tumour stem cells.

NNI is one of the institutions of SingHealth, the largest public healthcare group in Singapore. LSCDD, a wholly owned subsidiary of the US-based biopharmaceutical company, Eli Lilly and Company has recently expanded its facility at the Biopolis, and has cancer as one of its disease areas of focus. SICS is one of the research institutes of Singapore's A*STAR (Agency for Science, Technology and Research).

The research collaboration will leverage earlier findings by NNI research scientist Dr. Carol Tang, and Dr. Christopher Ang Beng Ti, a NNI neurosurgeon and SICS clinical investigator. The duo have shown that primary brain tumours are caused by a minority group of cells that display a genetic profile distinct from that of the tumour bulk.

They have reliably established a method of cryopreservation for these tumour-initiating cells (frequently termed "cancer stem cells"), thus facilitating the development of a brain tumour stem cell repository for future research and drug screening efforts. These important discoveries were published late last year in the journal Stem Cells. (http://www.a-star.edu.sg/biopolis/288-Press-Release?iid=576)

"Our scientific goals are to understand if and how we can target adult brain tumour stem cells selectively, and to use bioinformatics to identify novel biomarkers and new drug target," said Drs. Tang and Ang. "Ultimately, this could lead to new approaches to treat brain tumours."

The researchers have reason to be optimistic. This collaboration is the first amongst staff from Eli Lilly and Company and lead Singapore research agencies, NNI and A*STAR. With increased opportunities for exchanging ideas and synergising efforts, more effective and less invasive cancer treatment is now one step closer to becoming a reality.

Dr. Jonathon D. Sedgwick, LSCDD Managing Director and Chief Scientific Officer, said that "discovering new, breakthrough medicines through translational and clinical research requires intensive collaborations amongst partners. This research collaboration with clinicians and scientists from NNI and SICS will bring together different expertise and resources. This fits well with Lilly's new collaborative model known as the Fully Integrated Pharmaceutical Network (FIPNet) model, and will enhance and accelerate Lilly's ability to find 'Answers That Matter'."

Dr. Judith Swain, SICS Executive Director, said that "this collaboration is aligned with our focus on disease-oriented clinical and translational research. The family of clinician scientists here at SICS is well positioned to perform critical work at the border between basic and clinical research. We look forward to working closely with LSCDD and NNI to develop cutting-edge approaches for novel drug development."

"NNI's research aims to improve treatment and discover cures for neurological disease. This collaboration will enable all parties to benefit from the exchange of multidisciplinary expertise and will expedite the translation of research findings into clinical practice," said Prof. Lee Wei Ling, Executive Director of NNI.


'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related biology news :

1. Singapore National Science and Technology Awards
2. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
3. Rare cancer-causing syndrome found, for the first time, in Singapore
4. Ludwig Institute for Cancer Research to set up its first Asian branch in Singapore
5. Singapores BIOPOLIS and FUSIONOPOLIS on stage in Boston this week
6. Singapore opens Fusionopolis, its second major R&D hub in 5 years
7. Singapore research team first place in Brain-Computer Interface contest
8. NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition
9. Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy
10. Research shows skeleton to be endocrine organ
11. Newly created cancer stem cells could aid breast cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):
(Date:9/20/2017)... ... September 20, 2017 , ... From industry leaders, sports stars, and Hollywood ... failed. Many of these people had lost all hope. Their stories are ... Download (pdf) , “Neil takes readers on a riveting journey through the ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... building management solutions, announced today the opening of an office in Taipei, Taiwan. ... the Greater China region, while developing new relationships in the region. Located in ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... hood and a high-performance fume hood. Along with the advantages and disadvantages of ... ductless vs. ducted hoods in the laboratory. , Attendees will learn from an ...
(Date:9/19/2017)... ... ... CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an interview with Dr. ... Dr. Harman and Dr. Riordan met in 2003 and have remained in contact over ... cell therapy and a fast friendship was formed. , Dr. Harman has been a leader ...
Breaking Biology Technology: